Osteocalcin levels decrease during the treatment of an acute depressive episode
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076723" target="_blank" >RIV/65269705:_____/22:00076723 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/22:00126850
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fpsyt.2022.893012/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fpsyt.2022.893012/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fpsyt.2022.893012" target="_blank" >10.3389/fpsyt.2022.893012</a>
Alternative languages
Result language
angličtina
Original language name
Osteocalcin levels decrease during the treatment of an acute depressive episode
Original language description
ObjectivesOsteocalcin is a protein secreted by osteoblasts with a versatile endocrine role. Several domains in which it plays a role-stress response, monoamine synthesis, and cognitive functioning-are implicated also in the pathophysiology of major depressive disorder. In search of possible objective biomarkers of depression, the aim of the study was to assess the relationship between osteocalcin and depressive symptoms during the treatment of depressive episode. MethodsThe study included female inpatients with at least moderate depressive episode. In these patients, depression severity was measured using the Montgomery-angstrom sberg Depression Rating Scale (MADRS), and osteocalcin levels were assessed before the stabilization of antidepressive treatment and after 6 weeks. Relationships between osteocalcin levels and symptoms were analyzed with mixed-effect and linear models, taking into account age, menopausal status, and body mass index. ResultsIn 11 out of 13 enrolled inpatients, osteocalcin levels decreased during the first 6 weeks of treatment; this decrease was significant according to the mixed-effects model (t = -2.345, p = 0.019). According to the linear model, this decrease was significantly associated with reduction in depressive symptom severity (t = 2.673, p = 0.028). Osteocalcin was not associated with initial depressive symptom severity, and initial osteocalcin levels did not predict response to treatment. Limitations of the study include low sample size and inclusion of both pre- and postmenopausal women of various ages. ConclusionsThis preliminary study suggests that osteocalcin may be a candidate biomarker of antidepressive treatment response and that this topic warrants further investigation.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30215 - Psychiatry
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Psychiatry
ISSN
1664-0640
e-ISSN
1664-0640
Volume of the periodical
13
Issue of the periodical within the volume
Aug
Country of publishing house
CH - SWITZERLAND
Number of pages
8
Pages from-to
893012
UT code for WoS article
000841615400001
EID of the result in the Scopus database
2-s2.0-85136913980